Renovaro, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US29350E1047
USD
1.30
0.04 (3.17%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Renovaro, Inc. stock-summary
stock-summary
Renovaro, Inc.
Pharmaceuticals & Biotechnology
Enochian Biosciences Inc, formerly DanDrit Biotech USA, Inc., is a Denmark-based biotechnology company. The Company focuses on developing vaccine against colorectal cancer. It has developed various vaccines that are used in various clinical trials in Europe and Asia, including MelCancerVac (MCV) for treatment of cancer (one phase I/II trial in Denmark and two phase II trials in Denmark and Singapore), Tolerogenic (producing immunologic tolerance) dendritic cell (TDC) (pre-clinical stage in Denmark), and Melvaccine (MV), a melanoma cell lysate used as standalone vaccine (pre-clinical state in Denmark). The Company offers MCV platform technology, which is a cellular immunotherapy for treatment of cancer. Also, the Company develops gene therapies for patients with human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS).
Company Coordinates stock-summary
Company Details
Century City Medical Plaza, 2080 Century City East LOS ANGELES CA : 90067
stock-summary
Tel: 1 212 7630184
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 20 Schemes (8.55%)

Foreign Institutions

Held by 31 Foreign Institutions (1.14%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Rene Sindlev
Independent Chairman of the Board
Dr. Mark Dybul
Executive Vice Chairman of the Board, Principal Executive Officer
Mr. Henrik Gronfeldt-Sorensen
Director
Mr. Gregg Alton
Independent Director
Dr. Carol Brosgart
Independent Director
Ms. Evelyn D'An
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
0 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 43 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.06

stock-summary
Return on Equity

-24.90%

stock-summary
Price to Book

0.49